BuSpar patent appeal
Executive Summary
U.S. appeals court to hear oral arguments on BuSpar patent infringement lawsuit July 12. The court earlier denied Bristol-Myers Squibb's motion for a stay of the D.C. federal court's order to delist a BuSpar metabolite patent from the "Orange Book" and approve generic buspirone (1"The Pink Sheet" April 2, p. 28). Mylan filed suit against Bristol and FDA Nov. 30
You may also be interested in...
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
Par Pharmaceutical hopes to capture a portion of the 15 mg buspirone market with the March 28 approval of its 7.5 mg strength of the anxiety drug buspirone, a generic equivalent of Bristol-Myers Squibb's BuSpar. Par has 180-day exclusivity for 7.5 mg buspirone.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials